What is driving MEM Share Price?, page-95

Some information that some may not know...

Alison Coutts currently heading Memphasys. She was the first female graduate Melbourne University Chem Engineering, followed by Professor Sandra Kentish, who is now Head of Chemical and Biomedical Engineering at the University of Melbourne, and now involved with Memphasys.

MBA with Distinctions from Melbourne Business School
CRA prize in Business Policy Winner
Grad Diploma in Biotechnology University of Melbourne
Director of Corporate Advisory for Martin Place Securities
Co-founder EG Capital
25 years experience in international engineering project management, strategy consulting.
Vast experience in venture capital, stock broking & investment banking.
Chairman of the external advisory council for CSIRO's Health Sector projects.
Member of the advisory panel to the ASX for latest code of best practice for reporting companies.
Head of the Securities Institute's Masters Degree course in Biotechnology.

John Aikin who wanted equity rather than money, is number 5 holder on the T20 list. He is a Laureate Professor and Director of the University of Newcastle priority research Centre for Reproductive Science. He will be developing the assessment protocols with the IVF Clinics (KOL's). Absolute godfather of the fertility game here, involved putting his expertise and name to this company.

During the large volume days, none of the top 3 who own most of the shares sold a single unit. The recent investment by Bob Peters investment still holds his shares. Despite there being only small freefloat around 90 million units left, the trading volume on those rally days obviously was recycled shares. IMO very undervalued, product that works, market that needs it. Quick path to commercialisation, KOL's all lined up. Wouldn't be suprised if its taken out later on down the track.